BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18844220)

  • 1. How many cervical cancers are prevented by treatment of screen-detected disease in young women?
    Sasieni P; Castanon A; Parkin DM
    Int J Cancer; 2009 Jan; 124(2):461-4. PubMed ID: 18844220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of screening episodes linked to CIN3 and invasive cancer registrations to study outcomes from the NHS Cervical Screening Programme.
    Blanks RG; Moss SM; Coleman DA; Addou S; Swerdlow AJ
    Cytopathology; 2009 Jun; 20(3):154-60. PubMed ID: 19207309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic increase in cervical cancer registrations in young women in 2009 in England unlikely to be due to the new policy not to screen women aged 20-24.
    Sasieni P; Castanon A
    J Med Screen; 2012 Sep; 19(3):127-32. PubMed ID: 23093730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical screening: why young women should be encouraged to be screened.
    Herbert A; Holdsworth G; Kubba AA
    J Fam Plann Reprod Health Care; 2008 Jan; 34(1):21-5. PubMed ID: 18201402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer.
    Barrett JE; Sundström K; Jones A; Evans I; Wang J; Herzog C; Dillner J; Widschwendter M
    Genome Med; 2022 Oct; 14(1):116. PubMed ID: 36258199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive cervical cancer audit: why cancers developed in a high-risk population with an organised screening programme.
    Herbert A; Anshu ; Culora G; Dunsmore H; Gupta SS; Holdsworth G; Kubba AA; McLean E; Sim J; Raju KS
    BJOG; 2010 May; 117(6):736-45. PubMed ID: 20184570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme.
    Luyten A; Buttmann-Schweiger N; Luyten K; Mauritz C; Reinecke-Lüthge A; Pietralla M; Meijer CJ; Petry KU
    Int J Cancer; 2014 Sep; 135(6):1408-16. PubMed ID: 24519782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.
    McCredie MR; Sharples KJ; Paul C; Baranyai J; Medley G; Jones RW; Skegg DC
    Lancet Oncol; 2008 May; 9(5):425-34. PubMed ID: 18407790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease.
    Macgregor JE; Campbell MK; Mann EM; Swanson KY
    BMJ; 1994 May; 308(6941):1407-11. PubMed ID: 8019250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cervical cancer screening in Italy: quality of colposcopy and treatment. 2010 activity].
    Volante R; Giubilato P; Ronco G
    Epidemiol Prev; 2012; 36(6 Suppl 1):78-86. PubMed ID: 23293272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Three-year follow-up results of visual inspection with acetic acid/Lugol's iodine (VIA/VILI) used as an alternative screening method for cervical cancer in rural areas].
    Zhang YZ; Ma JF; Zhao FH; Xiang XE; Ma ZH; Shi YT; Hu SY; Qiao YL
    Chin J Cancer; 2010 Jan; 29(1):4-8. PubMed ID: 20038302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
    Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
    Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus and Papanicolaou tests to screen for cervical cancer.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Johansson B; Forslund O; Hansson BG; Rylander E; Dillner J
    N Engl J Med; 2007 Oct; 357(16):1589-97. PubMed ID: 17942872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
    Silver MI; Schiffman M; Fetterman B; Poitras NE; Gage JC; Wentzensen N; Lorey T; Kinney WK; Castle PE
    Cancer; 2016 Dec; 122(23):3682-3686. PubMed ID: 27657992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.